Table 2 Univariate and multivariate analyses of associations between various pre-treatment parameters and overall survival

Age > = 72 years

2.38

1.23–4.60

0.01

4.07

1.68–9.90

<0.01

ECOG PS > =1

2.92

1.59–5.51

<0.01

2.18

1.00–4.77

0.05

Significant pain

1.72

0.94–3.15

0.08

1.37

0.63–2.96

0.43

PSA at prostate cancer diagnosis > = 125 ng/mL

1.06

0.58–1.95

0.85

Gleason score > = 8

0.7

0.38–5.78

0.26

Metastatic site

 Bone

1.49

0.80–2.77

0.21

 Lymph node

1.05

0.57–1.93

0.89

Prior treatment

 Prostatectomy

0.81

0.32–2.07

0.66

 Radiotherapy

1.14

0.57–2.27

0.72

Combination therapy

 Bisphosphonate

1.02

0.52–1.99

0.96

 Estramustine

2.52

0.99–6.47

0.05

1.35

0.49–3.68

0.56

PSA at docetaxel initiation

3.45

1.76–6.77

<0.01

2.36

1.02–5.45

<0.05

Androgen deprivation therapy administration period > = 30 months

0.46

0.25–0.85

0.01

0.76

0.37–1.54

0.44

Serum markers at the start of docetaxel therapy

 Hemoglobin > = 12 g/dL

0.24

0.12–0.48

<0.01

0.24

0.10–0.59

<0.01

 NLR > = 3

1.71

0.93–3.15

0.09

1.33

0.62–2.85

0.46

 Cre > = 0.8 mg/dL

0.68

0.37–1.26

0.22

 ALP > =300 IU/L

3.27

1.70–6.30

<0.01

0.87

0.34–2.22

0.76

 LDH > =230 IU/L

1.88

1.02–3.49

<0.05

1.24

0.62–2.46

0.55

 CRP-to-Albumin　Ratio > =7

1.7

0.92–3.12

0.09

2.34

0.91–6.05

0.08